Go Back

Member story

go back

Throughout history, if a person falls ill - trying to find answers to important questions for themselves: "What happened?", "What can be the consequences of the disease?", "How to cure?", "What measures to take to not get sick again?". In the XXI century, in the era of the information revolution, the most modern achievements of civilization help to answer these questions. Today the general, "hospital average" methods are being replaced by individual therapy that takes into account the characteristics of each patient's body. Back in 2015, the U.S. launched a program to develop precision medicine in the country, an intermediate step between the traditional approach and personalized medicine. The Precision Medicine Initiative program does not yet target treatment for a specific person, but it already includes the division of patients with the same genotype into groups. The U.S. National Institutes of Health received funding to create a cohort of 1 million volunteers. Scientists will monitor their health and well-being and create an impressive information base. In France, they emphasized the educational component - they introduced genetics and information technology: collection and analysis of genetic data arrays into the training program for doctors. In addition, the French government has adopted a program for the development of genomics and precision medicine until 2025. The goals are very ambitious: to study more than 230 thousand genomes, find cures for cancer and diabetes, and integrate genomic medicine into the French healthcare system. Private business also contributes to the development of personalized medicine. In 2002, Leroy Hood, head of the American Institute for Systems Biology, formulated the concept of "medicine of the future" - the 4Ps: predictive, preventive, personalized, participatory. From theory to practice, Hood co-founded Arivale, a company that uses genetic information to develop individualized programs to maintain health. Today's health care system actively combats disease through surgery and pharmacology. But treatment for a disease begins when it has already been diagnosed in a patient. And both diagnostics and treatment are based on the average indicators of the population, and the choice of tactics is limited to the options offered by the doctor. The situation is different in the concept of new medicine. In recent years, biology and medicine have evolved from sciences that study individual molecules into disciplines that practice an integral approach. Systems medicine performs extensive health screening and separates patients and diseases into different subgroups. Genetic data help segment people with different reactions to the same drug, with different disease risks and other clinically relevant factors. Diseases like breast cancer and Crohn's disease, once classified as uniform, are now stratified into different clinical subgroups based on genetic, molecular and cellular differences. The division helps make accurate diagnoses and select the most effective, targeted treatment. We can screen thousands of parameters, but how do we analyze them? This is where big data technologies come in. They process hundreds of thousands of parameters and give a volumetric picture that shows what specific proteins appeared in the cell in response to exposure or how the number of certain molecules in the body changed in different diseases. Identification of these biomarkers makes it possible to diagnose and treat diseases much earlier than it is possible today. Promoting healthy lifestyles, informing people about the risks - all this is done by social networks. As a result, people are more actively thinking about their health, finding motivation for prevention and treatment, making informed choices and taking responsibility for their health. Digital technology is another aspect of personalized medicine. In Germany, an artificial intelligence was taught to recognize brain tumors in a sample of 220 MRI patients. Then it was given images of meningioma in 56 patients and glioblastoma in 64 patients. The artificial intelligence described these abnormalities, and the results matched the radiologists' findings by more than 80%. The medicine of the future is digital, focused on early prevention and high-tech treatment. The advantages of a personalized approach are obvious and are already used in oncology practice - in targeted therapy, drugs are prescribed to the patient after a molecular genetic study of the tumor. The next step of personalization is molecular genetic analysis of the body, which should be performed when the patient is healthy enough. And finally, at the finish line, personalization will be integrated at all levels of screening and treatment. In the new key of health care, we will be able to detect diseases at the earliest stage and reverse them before they begin to develop. If knowledge is power, it is worth channeling it into control over one's health, well-being, and life.